658 related articles for article (PubMed ID: 33552069)
41. The Potential of Mesenchymal Stem Cells for the Treatment of Cytokine Storm due to COVID-19.
Li X; Yan M; Chen J; Luo Y
Biomed Res Int; 2021; 2021():3178796. PubMed ID: 34840969
[TBL] [Abstract][Full Text] [Related]
42. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines.
Zheng M; Karki R; Williams EP; Yang D; Fitzpatrick E; Vogel P; Jonsson CB; Kanneganti TD
Nat Immunol; 2021 Jul; 22(7):829-838. PubMed ID: 33963333
[TBL] [Abstract][Full Text] [Related]
43. Are all cytokine storms the same?
Panoskaltsis N
Cancer Immunol Immunother; 2021 Apr; 70(4):887-892. PubMed ID: 33416946
[TBL] [Abstract][Full Text] [Related]
44. Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19.
Zarei M; Sahebi Vaighan N; Ziai SA
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):633-643. PubMed ID: 34647511
[TBL] [Abstract][Full Text] [Related]
45. [Involvement of the complement cascade in severe forms of COVID-19].
Chouaki Benmansour N; Carvelli J; Vivier É
Med Sci (Paris); 2021 Apr; 37(4):333-341. PubMed ID: 33835019
[TBL] [Abstract][Full Text] [Related]
46. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
47. Immunological Aspects of SARS-CoV-2 Infection and the Putative Beneficial Role of Vitamin-D.
Peng MY; Liu WC; Zheng JQ; Lu CL; Hou YC; Zheng CM; Song JY; Lu KC; Chao YC
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065735
[TBL] [Abstract][Full Text] [Related]
48. Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2.
Tonk M; Růžek D; Vilcinskas A
Viruses; 2021 May; 13(5):. PubMed ID: 34069206
[TBL] [Abstract][Full Text] [Related]
49. Cytokine profiling in Iranian patients with COVID-19; association with clinical severity.
Taghiloo S; Soltanshahi M; Aliyali M; Abedi S; Mehravaran H; Ajami A; Asgarian-Omran H
Iran J Immunol; 2021 Mar; 18(1):54-64. PubMed ID: 33787514
[TBL] [Abstract][Full Text] [Related]
50. Complement cascade in severe forms of COVID-19: Recent advances in therapy.
Chouaki Benmansour N; Carvelli J; Vivier E
Eur J Immunol; 2021 Jul; 51(7):1652-1659. PubMed ID: 33738806
[TBL] [Abstract][Full Text] [Related]
51. Mathematical Modeling of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Network with Cytokine Storm, Oxidative Stress, Thrombosis, Insulin Resistance, and Nitric Oxide Pathways.
Sasidharakurup H; Kumar G; Nair B; Diwakar S
OMICS; 2021 Dec; 25(12):770-781. PubMed ID: 34807729
[TBL] [Abstract][Full Text] [Related]
52. Flavonoids against the SARS-CoV-2 induced inflammatory storm.
Liskova A; Samec M; Koklesova L; Samuel SM; Zhai K; Al-Ishaq RK; Abotaleb M; Nosal V; Kajo K; Ashrafizadeh M; Zarrabi A; Brockmueller A; Shakibaei M; Sabaka P; Mozos I; Ullrich D; Prosecky R; La Rocca G; Caprnda M; Büsselberg D; Rodrigo L; Kruzliak P; Kubatka P
Biomed Pharmacother; 2021 Jun; 138():111430. PubMed ID: 33662680
[TBL] [Abstract][Full Text] [Related]
53. Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications.
Hirawat R; Saifi MA; Godugu C
Life Sci; 2021 Feb; 267():118923. PubMed ID: 33358906
[TBL] [Abstract][Full Text] [Related]
54. The role and delicate balance of Host Immunity in Coronavirus Disease-19.
Vyas AK; Varma V; Garg G; Gupta P; Trehanpati N
Iran J Immunol; 2021 Mar; 18(1):1-12. PubMed ID: 33787510
[TBL] [Abstract][Full Text] [Related]
55. The role of HMGB1 in COVID-19-induced cytokine storm and its potential therapeutic targets: A review.
Wulandari S; Hartono ; Wibawa T
Immunology; 2023 Jun; 169(2):117-131. PubMed ID: 36571562
[TBL] [Abstract][Full Text] [Related]
56. The interplay between the immune system and SARS-CoV-2 in COVID-19 patients.
Shabbir S; Raza MH; Arshad M; Khan MJ
Arch Virol; 2021 Aug; 166(8):2109-2117. PubMed ID: 33950288
[TBL] [Abstract][Full Text] [Related]
57. Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome.
Azar MM; Shin JJ; Kang I; Landry M
Expert Rev Mol Diagn; 2020 Nov; 20(11):1087-1097. PubMed ID: 32990479
[TBL] [Abstract][Full Text] [Related]
58. COVID-19 and Neutrophils: The Relationship between Hyperinflammation and Neutrophil Extracellular Traps.
Borges L; Pithon-Curi TC; Curi R; Hatanaka E
Mediators Inflamm; 2020; 2020():8829674. PubMed ID: 33343232
[TBL] [Abstract][Full Text] [Related]
59. A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection.
Ahmed F
Front Immunol; 2020; 11():590459. PubMed ID: 33362771
[TBL] [Abstract][Full Text] [Related]
60. Implications of Low-grade Inflammation in SARS-CoV-2 Immunopathology.
Suárez-Reyes A; Villegas-Valverde CA
MEDICC Rev; 2021 Apr; 23(2):42. PubMed ID: 33974614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
